Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• The programmed death 1 (PD-1) receptor and its ligands (PD-L1, PD-L2) are key regulators of T cell coinhibition and exhaustion.
• Overexpression of PD-1 and PD-L1 in tumors and tumor-infiltrating lymphocytes is linked to poor prognosis in several cancers.
• Monoclonal antibodies targeting the PD-1/PD-L1 pathway are emerging as a significant cancer immunotherapy strategy.

Purpose of the Study:

• To review the role of the PD-1/PD-L1 pathway in cancer and the development of blocking monoclonal antibodies for immunotherapy.
• To highlight the clinical efficacy of PD-1/PD-L1 blockade in specific cancers like melanoma, NSCLC, RCC, and bladder cancer.
• To identify areas for future research, including response mechanisms, biomarker discovery, small-molecule inhibitors, and combination therapies.

Main Methods:

• Review of existing literature on PD-1/PD-L1 pathway in cancer.
• Analysis of clinical trial data for monoclonal antibodies targeting PD-1 and PD-L1.
• Synthesis of findings to outline current understanding and future directions.

Main Results:

• Monoclonal antibodies blocking the PD-1/PD-L1 pathway enhance T cell functions, leading to improved anti-tumor immunity.
• Significant response rates observed in clinical trials for melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and bladder cancer.
• The PD-1/PD-L1 pathway's role in T cell coinhibition and exhaustion is critical in cancer progression.

Conclusions:

• PD-1/PD-L1 pathway blockade represents a promising avenue for cancer immunotherapy, demonstrating clinical efficacy in various malignancies.
• Further investigation is required to understand variable patient responses, identify predictive biomarkers, and explore novel therapeutic strategies, including small-molecule inhibitors and combination treatments.